Jorge Boczkowski - Mécanismes fondamentaux de la... by nanomedTV

Of those whose works I follow which balance out the doom-and-gloom domain that can be nanotoxicity and nanopathogenesis, Dr. Laurent Lévy, PhD is one of the most sincere of nanomedicine researchers. Emphasising the medicine as much as the method, his nanoradiotherapeutics / nanotheragnostics team genuinely pursues its corporate aims while adhering to the principal precepts of the Corpus Hippocraticum maxim (Epidemics I.11)

"As to diseases, make a habit of two things — to help, or at least to do no harm."

Dr. Lévy is CEO of Nanobiotix® © - the translational, pioneering, SUNY at Buffalo spin-off which is devoted to revolutionising localised cancer treatment. Not engaging in the nanotech trend simply for novelty's sake, Nanobiotix® © incorporated existing standard radiation equipment while developing innovative radiotherapeutics products  based on high-energy physical mechanisms of actions which improve tumour control.

Nanobiotix® © is where the rubber meets the road in radiotherapy and it needs our votes as the favoured biotech company in the Buzz of BIO's Pipelines of Promise contest category at the BIO International Convention to rev up its development.

If the winner, Nanobiotix® © will garner complimentary Full Convention Access with Partnering. It may be selected to receive a free Company Presentation in the BIO Business Forum where Dr. Lévy and his group can demonstrate the worth of their intellectual capital.  

CLICK HERE TO VOTE

{One vote per person, per category}.

Voting closes on 30 April 2012.

http://www.laurentlevy.com/

http://www.nanobiotix.com/about-us/

DISCLOSURE: This blogger holds no position in nor possesses ties to Nanobiotix® © - financially, professionally, or personally - and derives no direct or indirect benefit therefrom.